Skip to NavigationSkip to content

Otila

Hanmi terminates lung cancer drug after being muscled out by AZ's Tagrisso

South Korea’s Hanmi Pharmaceutical has announced its intention to terminate development of its lung cancer drug Olita (olmutinib) as it admits that circumstances within the space have meant that continued R&D costs would “eclipse its value”.

“We found it difficult to find participants for our clinical studies because there is a medication that has already completed global phase 3 trials and is covered by insurance,” a spokesperson for the company said.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches